Correlation Engine 2.0
Clear Search sequence regions


  • antigen (hla)- drb1 (4)
  • azetidines (2)
  • hla dr (2)
  • hla drb1 (8)
  • hla drb1* 07 (8)
  • humans (1)
  • ligand (6)
  • liquid (1)
  • mass (1)
  • peptides (2)
  • vitro (4)
  • ximelagatran (11)
  • Sizes of these terms reflect their relevance to your search.

    Idiosyncratic ximelagatran-induced hepatotoxicity has been reported to be associated with human leukocyte antigen (HLA)-DRB1*07:01 and ximelagatran has been reported to inhibit the binding of the ligand peptide to HLA-DRB1*07:01 in vitro. In order to predict the possible interaction modes of ximelagatran with HLA-DR molecules, in silico docking simulations were performed. Molecular dynamics (MD) simulations were also performed to predict the effect of ximelagatran on the binding mode of the ligand peptide to HLA-DRB1*07:01. A series of in silico simulations supported the inhibitory effect of ximelagatran on the binding of the ligand peptide to HLA-DRB1*07:01 in vitro. Furthermore, direct interactions of ximelagatran with HLA-DR molecules were evaluated in vitro, which supported the simulated interaction mode of ximelagatran with HLA-DRB1*07:01. These results indicated that ximelagatran directly interacts with the peptide binding groove of HLA-DRB1*07:01 and competes with the ligand peptide for the binding site, which could alter the immune response and lead to the idiosyncratic ximelagatran-induced hepatotoxicity.

    Citation

    Makoto Hirasawa, Katsunobu Hagihara, Koji Abe, Osamu Ando, Noriaki Hirayama. In Silico and In Vitro Analysis of Interaction between Ximelagatran and Human Leukocyte Antigen (HLA)-DRB1*07:01. International journal of molecular sciences. 2017 Mar 24;18(4)

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 28338626

    View Full Text